• Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan)

    WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid European Hematology Association (EHA) Congress to be held June 9-12 in Vienna, Austria. Data to be presented reinforce the robust efficacy and safety profile of EMPAVELI® (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

    "Our presence at EHA this year continues to underscore the potential of EMPAVELI to become the new standard of care for all adults living with PNH," said…

    View Full Article
  1. WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase 19,031 shares of Apellis common stock and 23,332 restricted stock units (RSUs). The options have an exercise price of $44.96…

    View Full Article
  2. WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 8:40 a.m. PT .

    The event will be available via a live webcast from the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 30 days following the event.

    About Apellis 
    Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted…

    View Full Article
    • Generated $12.1 million in Q1 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenues
    • Reported 18-month data with intravitreal pegcetacoplan in geographic atrophy (GA); on track to submit NDA in 2Q 2022
    • Completed enrollment in potentially registrational Phase 2 study in amyotrophic lateral sclerosis (ALS); data expected mid-2023
    • Cash and investments of $965.3 million as of March 31, 2022 with expected cash runway into Q1 2024
    • Conference call scheduled today at 4:30 p.m. ET

    WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2022 financial results and business highlights.

    "2022 is a transformational year for…

    View Full Article
  3. WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, announced today that renowned hematologist Peter Hillmen, MB ChB, PhD, will join the company as head of hematology engagement, effective May 23, 2022.

    "For more than two decades, Dr. Hillmen has been at the leading edge of research in PNH, so we are thrilled to welcome him to the Apellis team," said Cedric Francois, MD, PhD, chief executive officer and co-founder of Apellis. "Dr. Hillmen's scientific expertise, combined with his deep understanding of PNH and its impact on patients, will be critical as we continue to bring EMPAVELI to patients."

    Dr. Hillmen is an internationally recognized…

    View Full Article